Research programme: antibody therapeutics - ImmunoBrain Checkpoint

Drug Profile

Research programme: antibody therapeutics - ImmunoBrain Checkpoint

Latest Information Update: 23 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Yeda
  • Developer ImmunoBrain Checkpoint
  • Class Antibodies; Antidementias
  • Mechanism of Action CD274 antigen inhibitors; PDCD 1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alzheimer's disease

Most Recent Events

  • 23 Jun 2017 Yeda has intellectual property rights for antibody therapeutics
  • 06 Jun 2017 Preclinical trials in Alzheimer's disease in Israel (PO)
  • 06 Jun 2017 Lundbeck and ImmunoBrain agree to develop antibody therapeutics for Alzheimer's disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top